乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义

doi:10.3969/j.issn.1004-616x.2021.03.013

Abstract

Abstract: OBJECTIVE： To investigate changes of Ki67 expression before and after neoadjuvant chemotherapy (NACT) in breast cancer as a predictor of therapeutic response and prognosis. METHODS： Retrospective analyses were conducted on 104 patients with breast cancer who received NACT at the Shantou University Medical College Cancer Hospital from December 2009 to September 2013. Expression of Ki67 was assessed using immunohistochemistry in pre-chemotherapy core-needle biopsy and post-surgical specimens. Clinicopathological characteristics， therapeutic responses， and survival were compared between the Ki67- reduced group and the Ki67-unchanged/increased group during NAC. RESULTS： Both the reduced and unchanged/increased groups accounted for 62.5% (65/104) and 37.5% (39/104)，respectively. Ki67 levels were significantly reduced in patients with higher Ki67 expression (63/91， P < 0.01) before NACT. Patients with reduced Ki67 after NAC showed significantly enhanced therapeutic response，such as clinical complete response and clinical partial response (59/65， P=0.005). In addition， the decreased value of Ki67 during NACT was significantly correlated with therapeutic response (r=0.302， P=0.002). The disease- free survival rates in the Ki67 reduced group was higher than that in the Ki67 unchanged/increase group (P=0.027). The overall survival rates in the Ki67 reduced group was higher than that in the Ki67 unchanged/increase group，but the difference was not statistically significant (P=0.171). CONCLUSION： The reduction of Ki67 expression after NACT could be a predictor for therapeutic response and prognosis in breast cancers.

Key words: Ki67, breast neoplasms, neoadjuvant chemotherapy, therapeutic response, prognosis

CLC Number:

R737.9

ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.

References

[1] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol, 2018, 19(1): 27-39.
[2] MARTELLI G, MICELI R, FOLLI S, et al. Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study[J]. Eur J Surg Oncol, 2017, 43(11): 2012-2020.
[3] BOUGHEY J C, SUMAN V J, MITTENDORF E A, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071(Alliance) clinical trial[J]. JAMA, 2013, 310(14): 1455-1461.
[4] 陈灿铭, 沈镇宙. 乳腺癌新辅助化疗疗效预测因子的研究现状[J]. 循证医学, 2007, 7(3): 132-134.
[5] TAN P H, BAY B H, YIP G, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death[J]. Mod Pathol, 2005, 18(3): 374-381.
[6] VINCENT-SALOMON A, ROUSSEAU A, JOUVE M, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy[J]. Eur J Cancer, 2004, 40(10): 1502-1508.
[7] VON MINCKWITZ G, SCHMITT W D, LOIBL S, et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer[J]. Clin Cancer Res, 2013, 19(16): 4521-4531.
[8] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
[9] CHEN C F, ZHANG Y L, HUANG Z Y, et al. Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer[J]. Cancer Biol Med, 2019, 16(3): 575-586.
[10] DOWSETT M, NIELSEN T O, A'HERN R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group[J]. J Natl Cancer Inst, 2011, 103(22): 1656-1664.
[11] CHEANG M C, CHIA S K, VODUC D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer[J]. J Natl Cancer Inst, 2009, 101(10): 736-750.
[12] YERUSHALMI R, WOODS R, RAVDIN P M, et al. Ki67 in breast cancer: prognostic and predictive potential[J]. Lancet Oncol, 2010, 11(2): 174-183.
[13] GOLDHIRSCH A, WINER E P, COATES A S, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223.
[14] JONES R L, SALTER J, A'HERN R, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer[J]. Breast Cancer Res Treat, 2010, 119(2): 315-323.
[15] TAN Q X, QIN Q H, YANG W P, et al. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy[J]. Int J Clin Exp Pathol, 2014, 7(10): 6862-6870.
[16] URRUTICOECHEA A, SMITH I E, DOWSETT M. Proliferation marker Ki-67 in early breast cancer[J]. J Clin Oncol, 2005, 23(28): 7212-7220.
[17] FASCHING P A, HEUSINGER K, HAEBERLE L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment[J]. BMC Cancer, 2011, 11: 486.
[18] ELLIS M J, TAO Y, LUO J Q, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics[J]. J Natl Cancer Inst, 2008, 100(19): 1380-1388.
[19] JONES R L, SALTER J, A’HERN R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer[J]. Breast Cancer Res Treat, 2009, 116(1): 53-68.
[20] ASSERSOHN L, SALTER J, POWLES T J, et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer[J]. Breast Cancer Res Treat, 2003, 82(2): 113-123.
[21] SUETA A, YAMAMOTO Y, HAYASHI M, et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?[J]. Surgery, 2014, 155(5): 927-935.
[22] KIM K I, LEE K H, KIM T R, et al. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients [J]. J Breast Cancer, 2014, 17(1): 40-46.
[23] CHEN R, YE Y, YANG C C, et al. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients [J]. Breast Cancer Res Treat, 2018, 170(1): 35-43.
[24] 余海云, 李文萍, 郜红艺, 等. 新辅助化疗疗效与乳腺癌Ki67、 P53表达的关系[J]. 中华乳腺病杂志: 电子版, 2011, 5(3): 297-305.
[25] DENKERT C, BUDCZIES J, VON MINCKWITZ G, et al. Strategies for developing Ki67 as a useful biomarker in breast cancer[J]. Breast, 2015, 24(Sup 2): S67-S72.
[26] PAIK S, SHAK S, TANG G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J]. N Engl J Med, 2004, 351(27): 2817-2826.
[27] SHERI A, SMITH I E, JOHNSTON S R, et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy[J]. Ann Oncol, 2015, 26(1): 75-80.
[28] YOSHIOKA T, HOSODA M, YAMAMOTO M, et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer[J]. Breast Cancer, 2015, 22(2): 185-191.

Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[2]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[3]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[4]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[5]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[6]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[7]	SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443.
[8]	DING Yawen, JIAO Wenjing, WANG Pengyu, LU Gang, MA Ming. Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 464-468,489.
[9]	SHAO Junguo, JIAO Wenjing, WANG Xuexiao, ZHANG Jinyan, MA Ming. Clinical significance of mi-429 and Bmi-1 mRNA expressions in lung carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 369-373.
[10]	Lü Yanping, WU Chuancheng, YANG Shuangfeng, HE Chenzhou, HAN Renjie, YAN Wei, LIU Baoying. Relationship between differentially expressed miRNA-SNPs and prognosis of gastric cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 380-386.
[11]	GUO Xiujuan, DU Yanyan, YAN Xi, ZHAO Xuetao, HAN Lina, WU Yipeng, WANG Xuexiao, MA Ming. Expression and clinical significance of CREB in esophageal squamous cell carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 387-390,394.
[12]	YANG Li, ZHANG Mengxian, ZHANG Wei, XIONG Yingyou, CHEN Shiyong, FANG Chengxiang. Data mining to investigate expression and significance of aurora kinase A in esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 221-228.
[13]	CHEN Xiuqiong, MENG Fanqiao, XIONG Hua, WANG Yali, ZHOU Yangmei, TANG Wenhua, ZOU Yanmei. Investigation and evaluation of gastric cancer core genes using bioinformatics [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(4): 308-314.
[14]	GAO Jie, ZHANG Xiao, WEI Chao. Involvement of differentially expressed miRNA in prognosis of pancreatic cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 173-179.
[15]	HU Jie, CHAO Jianqian. Utilizing the TCGA datasets to show clinical significance of FoxO1 expression in prostate cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 198-202.